Hospira, Inc. /quotes/zigman/346012/quotes/nls/hsp HSP -1.05% , the world’s leading provider of injectable drugs and infusion technologies, today reported results for the fourth quarter and full year ended Dec. 31, 2012. For the fourth quarter of 2012, net sales were $1.1 billion, and adjusted* diluted earnings per share were $0.55. (Adjusted* measures are adjusted for certain specified items as described later in this press release and the attached schedules.)
